PROCEPT BioRobotics Corp. PRCT shares are down during Thursday’s premarket session following the company’s recent financial results and updates on its revenue guidance. In its fourth quarter of 2025, ...
SAN JOSE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing ...
CEO Larry Wood provided an overview of organizational changes since his arrival, stating, "The next stage of PROCEPT's development requires shifting the operational focus towards increasing procedure ...
Hosted on MSN
Procept BioRobotics outlines $410M–$430M 2026 revenue target while accelerating utilization initiatives
Larry Wood, President and CEO, stated total revenue for the third quarter of 2025 was $83.3 million, highlighting strong execution, primarily driven by U.S. capital systems shipped, totaling 58 in the ...
2026 financial targets: PROCEPT expects $390–$410 million in revenue (27%–33% growth), 60,000–64,000 procedures, a 65% gross margin and an adjusted EBITDA loss of $30M to $17M with EBITDA turning ...
PROCEPT BioRobotics (NASDAQ:PRCT) stock is trading on Monday after the company released better-than-expected third-quarter earnings. The company reported EPS loss of $(0.40), down from $(0.51) a year ...
In its fourth quarter of 2025, PROCEPT BioRobotics reported total revenue of $76.4 million, marking a 12% increase compared to the prior year, missing the consensus of $94.14 million. The increase was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results